| Popis: |
Background: Oncohematological diseases have an increased incidence in Rheumatoid Arthritis (RA) patients. However, their trend in RA in Spain is unknown Objectives: To analyze the incidence and trend of hospital admissions for lymphomas and leukemias in RA patients in Spain from 1999–2015 Methods: We performed an observational retrospective population study analyzing the spanish administrative database that includes a Minimun Basic Data Set (MBDS) of hospital admissions of RA patients from 1999–2015. We selected MBDSs for lymphomas and leukemias. Cases were identified by the presence in primary/secondary diagnosis of ICD9 codes. The population at risk was estimated with a prevalence of RA of 0,5% (0,8% women and 0,2% men). Crude and adjusted rates were calculated, and the trend was analyzed using the Generalized Linear Model with the year as the analysis variable. SPSS version 20 (Chicago, IL) was used Results: 338.343 RA hospital admissions were detected, being 3561(1,1%) lymphomas (61,5% women, 38,5% men) and 1664(0,5%) leukemias (52,3% women, 47,7% men). Mean age 68,94(SD 11,38) in lymphomas and 71,46(SD 11,24) in leukemias. Age-adjusted rate during the period for lymphoma was 152,19/105 inhab/year (92,05 women and 240,14 men). Lymphoma age-adjusted rate increased from 52,46/105 inha/year in 1999 to 187,57 in 2015, both women (from 42,74 to 142,95) and men (from 280,77 to 326,63). An annual increase in lymphoma rate of 6,9% is estimated (RRI 1,069; CI 95% 1,054–1,085). Age-adjusted rate during the period for leukemia was 90,87/105 inhab/year (37,09 women and 144,65 men). Leukemia age-adjusted rate increased from 18,86/105 inhab/year in 1999 to 94,05 in 2015, both women (13,80 in 1999 to 65,93 in 2015) and men (38,70 in 1999 to 204,84 in 2015). An annual increase in leukemia rate of 8,2% is estimated (RRI 1,083; CI 95% 1,069–1,097). Conclusions: In Spain from 1999–2015 lymphoma and leukemia hospital admissions in RA patients increased, with an estimation of 6,9% and 8,2% annual increase respectively. Disclosure of Interest: None declared |
